PANDEIA THERAPEUTICS LIMITED
💤Zombieactive
11463856 · ltd · incorporated 2018-07-13
Investment thesis
Zombie company — trading but stalled; unlikely mover.
Why interesting: Quiet, steady; could be a succession or carve-out candidate with the right conversation.
Why risky: No growth signal; thin margin for error on price.
🔒Estimated value
—
Upgrade to see
Turnover
—
year to Dec 2024
Net worth
£-3.21M
book net assets
Opportunity
72/100
Strong
What this business does
Primary activity: Research and experimental development on biotechnology
Sector: Professional, scientific & technical
Investor take
Pass (distressed without resilience)Distressed active trading company — structural issues outweigh the discount.
Opportunity 72/100 (strong), bankability 75/100. High owner-dependency — earn-out structure likely required for clean transition. Share purchase looks the cleaner deal structure. Biggest value-creation lever: Broaden director team. Sole director creates succession risk and reduces buyer comfort. Appoint a second director or strong #2. Most likely exit: distressed disposal / insolvency (65/100).
Data confidence
Overall: medium (79/100)Adequate coverage. AI outputs are reliable for the sections scored high; verify the rest in diligence.
Company profile
address, 1 SIC codes, incorporation date
100
Financials
2 years of iXBRL accounts extracted (YoY deltas available) + narrative notes parsed
75
Lenders & charges
Confirmed no charges registered
85
Directors & officers
8 officers (2 active, 8 linked, 7 with DOB)
88
Ownership & PSC
1 active PSC(s) of 5 total, 5 with control declared
90
Director network
1 connected companies via shared directors
48
Filing history
64 filings on record
85
Gazette notices
No matching gazette notices (standard for active companies)
60
Opportunity Score
72/100Strong
PassWatchWorth a lookStrongExceptional
Solid opportunity signal. Worth a dedicated memo and management meeting.
Business quality
65
Adequate — check latest filings for context.
Acquirability
55
Some acquirability indicators.
Risk profile
85
Few red flags.
Signal strength
90
Good data coverage for analysis.
Signals from accounts
Derived from iXBRL accounts · accounting standard not declaredNegative net assets
Liabilities exceed assets by £3,214,073
Cash YoY
+25%
Year on year
Key financials
2 years extracted from filed iXBRL accountsCash
£223k
↑ 25% YoY
Net Worth
-£3.2m
↓ 148% YoY
Current Assets
£270k
↓ 38% YoY
Current Liabilities
—
Hover to see exact values · click legend to toggle series
Financials
Extracted from Companies House accounts · accounting standard unknown| Metric | 2024-12-31 | 2023-12-31 |
|---|---|---|
| Total assets | £142.4k | £275.4k |
| Current assets | £270.3k | £436.8k |
| Cash | £222.8k | £178.6k |
| Debtors | £47.5k | £258.2k |
| Net assets | £-3.21M | £-1.30M |
Amounts extracted automatically from iXBRL. Fields left blank were not reported or not mapped. Values in GBP unless stated.
🔒Filing-note intelligence
1 signal detected in this company's narrative notes — going-concern language, audit opinion, contingent liabilities, related-party transactions.
Available from the Pro tier upwards.
See pricing →Recent activity
Last 30 days
1
filing
- • 1 confirmation-statement
Last 90 days
1
filing
- • 1 confirmation-statement
Last 180 days
1
filing
- • 1 confirmation-statement
Counts from Companies House filing history.
Corporate timeline (35 events)Click to expand
- 2025-09-28📄accounts-with-accounts-type-smallaccounts · AA
- 2025-02-14📄memorandum-articlesincorporation · MA
- 2025-02-14📄resolutionresolution · RESOLUTIONS
- 2024-09-26📄accounts-with-accounts-type-smallaccounts · AA
- 2024-04-30📍change-registered-office-address-company-with-date-old-address-new-addressaddress · AD01
- 2024-04-29📄appoint-person-director-company-with-name-dateofficers · AP01
- 2024-04-29📄termination-director-company-with-name-termination-dateofficers · TM01
- 2024-04-26➕RHODES, Jennifer appointeddirector
- 2024-04-26➖KIM, Austin resigneddirector
- 2023-12-06📄change-account-reference-date-company-current-extendedaccounts · AA01
- 2023-06-28📍change-sail-address-company-with-old-address-new-addressaddress · AD02
- 2023-06-28📄notification-of-a-person-with-significant-controlpersons-with-significant-control · PSC02
- 2023-01-04📄appoint-person-director-company-with-name-dateofficers · AP01
- 2023-01-04📄memorandum-articlesincorporation · MA
- 2023-01-04📄resolutionresolution · RESOLUTIONS
- 2023-01-03📄termination-director-company-with-name-termination-dateofficers · TM01
- 2023-01-03📄termination-director-company-with-name-termination-dateofficers · TM01
- 2023-01-03📄termination-director-company-with-name-termination-dateofficers · TM01
- 2023-01-03📄cessation-of-a-person-with-significant-controlpersons-with-significant-control · PSC07
- 2022-12-22➖DE RUBERTIS, Francesco resigneddirector
- 2022-12-22➖GRAINGER, David John, Dr resigneddirector
- 2022-12-22➕KIM, Austin appointeddirector
- 2022-12-22➖MURRAY, John Fraser, Dr resigneddirector
- 2022-10-05📄accounts-with-accounts-type-smallaccounts · AA
- 2022-08-03📄change-account-reference-date-company-current-shortenedaccounts · AA01
- 2022-05-19📄second-filing-capital-allotment-sharescapital · RP04SH01
- 2019-09-19➕DE RUBERTIS, Francesco appointeddirector
- 2019-09-19➕GRAINGER, David John, Dr appointeddirector
- 2019-09-19➖QUIBELL, Martin resigneddirector
- 2019-08-09➕THE CAMBRIDGE PARTNERSHIP LIMITED appointedcorporate-secretary
- 2019-07-30➖SCHULZ-UTERMOEHL, Timothy, Dr resigneddirector
- 2019-03-05➕MURRAY, John Fraser, Dr appointeddirector
- 2019-03-05➕QUIBELL, Martin appointeddirector
- 2018-07-13🏢Company incorporatedAs PANDEIA THERAPEUTICS LIMITED
- 2018-07-13➕SCHULZ-UTERMOEHL, Timothy, Dr appointeddirector
Owner dependency
75/100
High — earn-out structure requiredMaterial founder dependency. Consider a 2-3 year earn-out and build in a handover plan before completion.
FACTORS
- +Sole director: Only one active director — all governance concentrated on one person.
Succession & seller-readiness
45/100
Moderate signalSome succession indicators present. Worth watching; approach if sector/strategy fits.
SIGNALS
- primarySole active director: Only one director in control. No visible successor — buyers solve the succession problem.
Red flags
cleanNo red flags detected from available public data. (This is not a clean bill of health — detailed accounts review still recommended.)
Group structure
Acadia Pharmaceuticals Inc. is the ultimate parent — holding 75%+ shares. This company sits inside their group.
🏛️ultimate parent
Acadia Pharmaceuticals Inc.
Corporate parent · holds 75-100% shares
⬇
PANDEIA THERAPEUTICS LIMITED
This company · 11463856
Parent relationships inferred from Persons with Significant Control filings. Full subsidiary tree requires reverse-lookup (coming).
Shareholders & ownership
1 active beneficial owner · dominant holder ≥75%| Name | Shares | Voting rights | Nature of control | Notified |
|---|---|---|---|---|
Acadia Pharmaceuticals Inc. Corporate entity | 75–100% | — | 75-100% shares | 22/12/2022 |
4 historic (ceased) PSCs
- Medicxi Ventures I Lpceased 22/12/2022· 75-100% shares
- Dr Fraser Murrayceased 05/03/2019· 25-50% shares · 25-50% voting · board control
- Mr Martin Quibellceased 05/03/2019· 25-50% shares · 25-50% voting · board control
- Dr Timothy Schulz-Utermoehlceased 20/09/2019· 75-100% shares · 75-100% voting · board control
From Companies House Persons with Significant Control filings. Share ranges are banded per the public PSC regime.
🔒Co-director network graph
Radial SVG graph showing every company connected via shared directors, colour-coded by status.
Available from the Pro tier upwards.
See pricing →Similar companies
Active · Professional services · CB postcode area| Company | Est. value | Turnover | Net worth | Staff | Age | Opp | Director |
|---|---|---|---|---|---|---|---|
| ALPHUBEL LTD→ 12541436 · est 2020 · no financials extracted | — | — | — | — | 6y | — | — |
| AMAREW LIMITED→ 12125934 · est 2019 · no financials extracted | — | — | — | — | 6y | — | — |
| AMBERDEN ASSOCIATES LTD→ 13813377 · est 2021 · no financials extracted | — | — | — | — | 4y | — | — |
| ANAGALLIS COMMUNICATIONS LTD→ 10007852 · est 2016 · no financials extracted | — | — | — | — | 10y | — | — |
| ANAIRE LTD→ 16317773 · est 2025 · no financials extracted | — | — | — | — | 1y | — | — |
| ANGEL NEWMARKET LIMITED→ 16489949 · est 2025 · no financials extracted | — | — | — | — | — | — | — |
| ANGLIA SELF STORAGE LIMITED→ 05227695 · est 2004 · no financials extracted | — | — | — | — | 21y | — | — |
| ANGLIAN ACCOUNTING SUPPORT LTD→ 07612731 · est 2011 · no financials extracted | — | — | — | — | 14y | — | — |
| ANGLICA CONSULTANCY LTD→ 16371372 · est 2025 · no financials extracted | — | — | — | — | 1y | — | — |
| ANN PETTENGELL LIMITED→ 07643609 · est 2011 · no financials extracted | — | — | — | — | 14y | — | — |
| ANNA HALL LIMITED→ 08059705 · est 2012 · no financials extracted | — | — | — | — | 13y | — | — |
| ANNA KENNERLEY LIMITED→ 12137546 · est 2019 · no financials extracted | — | — | — | — | 6y | — | — |
Peers ranked by estimated value, then turnover, then opportunity score.See all →
🔒Tailored diligence questions
7 specific questions generated from this company's actual signals — liquidity, leverage, director age, charge count, red flags, age-of-company.
Available from the Pro tier upwards.
See pricing →🔒Advanced scoring suite
Exit-route ranking, improvement thesis, quiet-distress detector, covenant-pressure proxy, extraction monitor, approaching triggers, ownership drift, local cluster, value trap, debt capacity, archetype classification — 48+ scoring modules.
Available from the Pro tier upwards.
See pricing →Company details
Statusactive
Typeltd
Incorporated2018-07-13
Jurisdictionengland-wales
Primary SIC72110 — Research and experimental development on biotechnology
Registered office
The Cambridge Partnership The Dorothy Hodgkin Bldg Babraham Research Campus
Babraham
Cambridge
CB22 3FH
England
Filing status
Accounts
Next due: 2026-09-30
Last made up to: 2024-12-31
Confirmation statement
Next due: 2027-07-10
Last: 2026-06-26
Officers (2 active · 6 resigned)
THE CAMBRIDGE PARTNERSHIP LIMITED→
Activecorporate-secretary · appointed 2019-08-09
View their other companies + combined net worth →
RHODES, Jennifer→
Activedirector · ~56y · appointed 2024-04-26
View their other companies + combined net worth →
DE RUBERTIS, Francesco→
Resigneddirector · ~56y · appointed 2019-09-19 · resigned 2022-12-22
GRAINGER, David John, Dr→
Resigneddirector · ~60y · appointed 2019-09-19 · resigned 2022-12-22
KIM, Austin→
Resigneddirector · ~63y · appointed 2022-12-22 · resigned 2024-04-26
MURRAY, John Fraser, Dr→
Resigneddirector · ~55y · appointed 2019-03-05 · resigned 2022-12-22
QUIBELL, Martin→
Resigneddirector · ~60y · appointed 2019-03-05 · resigned 2019-09-19
SCHULZ-UTERMOEHL, Timothy, Dr→
Resigneddirector · ~54y · appointed 2018-07-13 · resigned 2019-07-30
Click a director name to see their full track record across all companies.
Recent filings (64 total)
confirmation-statement-with-no-updates
confirmation-statement · CS01
2026-06-30
accounts-with-accounts-type-small
accounts · AA
2025-09-28
confirmation-statement-with-no-updates
confirmation-statement · CS01
2025-06-26
memorandum-articles
incorporation · MA
2025-02-14
resolution
resolution · RESOLUTIONS
2025-02-14
accounts-with-accounts-type-small
accounts · AA
2024-09-26
confirmation-statement-with-no-updates
confirmation-statement · CS01
2024-06-26
change-registered-office-address-company-with-date-old-address-new-address
address · AD01
2024-04-30
appoint-person-director-company-with-name-date
officers · AP01
2024-04-29
termination-director-company-with-name-termination-date
officers · TM01
2024-04-29
change-account-reference-date-company-current-extended
accounts · AA01
2023-12-06
confirmation-statement-with-updates
confirmation-statement · CS01
2023-07-04
change-sail-address-company-with-old-address-new-address
address · AD02
2023-06-28
notification-of-a-person-with-significant-control
persons-with-significant-control · PSC02
2023-06-28
appoint-person-director-company-with-name-date
officers · AP01
2023-01-04